Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-14

Clinical Trial Update: Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 safety and toxicity study of sorafenib in patients with renal cell carcinoma completed; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)

Snippet

Sponsor: Stanford University | Conditions: Carcinoma, Renal Cell, Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-01-14